Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Roundhill Innov-100 0DTE Covered Call Strat ETF (QDTE) vs Stryker Corporation (SYK) Price & Performance

Roundhill Innov-100 0DTE Covered Call Strat ETFTrade
Stryker CorporationTrade

Price performance (Past 24H)

Key statistics

Roundhill Innov-100 0DTE Covered Call Strat ETF vs Stryker Corporation — how do they compare? Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $29.47 (market cap $962.24M), while Stryker Corporation trades at $278.24 (market cap $106.24B). The key difference: Stryker Corporation is far larger — about 110.4× Roundhill Innov-100 0DTE Covered Call Strat ETF's market cap, and Stryker Corporation pays a 1.27% dividend while Roundhill Innov-100 0DTE Covered Call Strat ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Roundhill Innov-100 0DTE Covered Call Strat ETF for 56 Days and Stryker Corporation for 20 Days on average.

QDTESYK
Market Cap
$962.24M$106.24B
Volume
882,8592,982,001
Sector
Income / Options OverlayHealth
52-Week High
$36.60$388.35
52-Week Low
$26.85$269.75
Typical Hold Time
56 Days20 Days
Enterprise Value
—$117.70B
Dividend Yield
—1.27%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Roundhill Innov-100 0DTE Covered Call Strat ETF

QDTE trades at $29.89, down 0.3% with a bullish technical signal despite overbought RSI readings. The ETF generates weekly income through covered call strategies but faces concerns about NAV erosion and return of capital. Recent distributions have declined from $0.28 to $0.11, reflecting shrinking yields as volatility decreases. The fund's 0.97% expense ratio consumes significant portions of payouts, creating structural challenges for long-term value preservation.

The outlook remains cautious as high distribution yields mask underlying NAV deterioration. While weekly income appeals to retail investors, the strategy underperforms in bull markets and faces sustainability questions. Key risks include volatility dependency, return of capital concerns, and competitive pressure from alternative income ETFs. Analyst sentiment is mixed with recent downgrades highlighting structural weaknesses.

Stryker Corporation

Stryker (SYK) trades at $279.15, up 1.36% on the day, amid a mixed technical and fundamental backdrop. The stock shows bearish technical signals with key support at $268 and resistance at $284, while fundamentals remain solid with a 14.43% net income margin and strong analyst consensus of 71% buy ratings. Recent news highlights ongoing legal scrutiny over manufacturing issues, but the company maintains robust cash flow and earnings growth, with Q3 2026 results pending.

Outlook: SYK offers growth potential with a consensus price target of $368.11, supported by profitability and innovation, but faces near-term risks from legal investigations and technical weakness. Investors should weigh strong fundamentals against sentiment headwinds.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

QDTE
100% Buy0% Sell
Avg holding period · 56 Days
SYK
1% Buy99% Sell
Avg holding period · 20 Days

Top news

Latest headlines on both assets

About Roundhill Innov-100 0DTE Covered Call Strat ETF

QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.

Read more on QDTE →

About Stryker Corporation

Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.

Read more on SYK →